← Back to patent-cliff list
CAS 853908-50-6
6-bromo-3-nitroquinolin-4-ol
Codes: DACT-012
Application context (from source-drug indications)
COVID-19DactolisibRespiratory tract infectionDactolisibBreast cancerDactolisib呼吸障碍DactolisibSolid tumourDactolisibPancreatic neuroendocrine tumourDactolisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dactolisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-(4-nitrophenyl)acetonitrile→2-methyl-2-(4-nitrophenyl)propanenitrile→2-(4-aminophenyl)-2-methylpropanenitrile→6-bromo-4-chloro-3-nitroquinoline→2-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile→2-(4-((3-amino-6-bromoquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile→2-(4-(8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile→2-(4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile→quinolin-3-ylboronic acid→2-amino-5-bromobenzoic acid→(E)-5-bromo-2-((2-nitrovinyl)amino)benzoic acid→6-bromo-3-nitroquinolin-4-ol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.